References
- Ajit SN, David D, Danchen G. (2007). Stable drug encapsulation in micelles and microemulsions. Int J Pharm 345:9–25
- Aprile C, Marinone G, Saponaro R, et al. (1995). Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 22:1393–401
- Aprile C, Saponaro R, Villa G, et al. (1986). Assessment of split renal function with 99mTc-aprotinin. Eur J Nucl Med 12:37–40
- Bianchi C, Donadio C, Tramonti G, et al. (1984). 99mTc Aprotinin: a new tracer for kidney morphology and function. Eur J Nucl Med 9:257–60
- Bjerregaard S, Andersen LW, Stephens RW, et al. (2001). Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin. J Control Release 71:87–98
- Bode W, Huber R. (1992). Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204:433–51
- Buluç M, Gürdal H, Melli M. (2002). Effect of misoprostol and indomethacin on cyclooxygenase induction and eicosanoid production in carrageenan-induced air pouch inflammation in rats. Prostaglandins Other Lipid Mediat 70:227–39
- Burke MD, Staton JS, Viskers AW, et al. (2007). A novel method to radiolabel gastric retentive formulations for gamma scintigraphy assessment. Pharm Res 24:695–704
- Edward LA. (1993). Clinically Based classification system for acute pancreatitis: summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11 through 13, 1992. Arch Surg 128:586–90
- Ege MA, Karasulu HY, Guneri T. (2004). Triangle phase diagram analysis software. Presented at: The 4th International Postgraduate Research Symposium on Pharmaceutics, Istanbul, Turkey. 46, 36
- Ellis-Behnke R, Teather L, Schneider G, So K. (2007). Using nanotechnology to design potential therapies for CNS regeneration. Curr Pharm Des Pharm 13:2519–28
- Gabizon AA, Tzemach D, Horowitz AT, et al. (2006). Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res 12:1913–20
- Graf A, Ablinger E, Peters S, et al. (2008). Microemulsions containing lecithin and sugar-based surfactants: nanoparticle templates for delivery of proteins and peptides. Int J Pharm 350:351–60
- Häfeli U. (2002). Radioactive microspheres for medical applications. In: De Cuyper M, Bulte JWM, eds. Physics and chemistry basis of biotechnology. Kluwer Academic Publishers, Springer Netherlands, 213–48
- Han S, Chong V, Murray T, et al. (2007). Preliminary experience of 99mTc-Aprotinin scintigraphy in amyloidosis. Eur J Haematol 79:494–500
- Henry DA, Carless PA, Moxey AJ, et al. (2011). Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev CD001886. doi: 10.1002/14651858.CD001886.pub3
- Hunt BJ, Segal H, Yacoub M. (1992). Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 86:410–12
- Kalkat M, Levine A, Dunning J. (2004). Does use of aprotinin in coronary artery bypass graft surgery affect graft patency? Interact Cardiovasc Thorac Surg 3:124–8
- Karasulu HY, Oruç N, Üstündağ-Okur N, et al. (2015). Aprotinin revisited: formulation, characterization, biodistribution and therapeutic potential of new aprotinin microemulsion in acute pancreatitis. J Drug Target 23:525–37
- Kedar U, Phutane P, Shidhaye S, Kadam V. (2010). Advances in polymeric micelles for drug delivery and tumor targeting. – Nanomedicine Nanotechnol 6:714–29
- Kim K. (2007). Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 3:103–10
- Krauser JA. (2013). A perspective on tritium versus carbon-14: ensuring optimal label selection in pharmaceutical research and development. J Labelled Comp Radiopharm 56:441–6
- Park K. (2007). Nanotechnology: what it can do for drug delivery. J Control Release 120:1–3
- Rustom R, Grime S, Maltby P, et al. (1992). A new method to measure renal tubular degradation of small filtered proteins in man using radiolabelled aprotinin (Trasylol). Clin Sci 83:289–94
- Schaadt BK, Hendel HW, Gimsing P, et al. (2003). 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 44:177–83
- Smith M, Kocher HM, Hunt BJ. (2009). Aprotinin in severe acute pancreatitis. Int J Clin Pract 64:84–92
- Smyth DR, Tsopelas C. (2005). An improved (99m)Tc-aprotinin kit formulation: quality control analysis of radiotracer stability and cold kit shelf life. Nucl Med Biol 32:885–9
- Tiourina O, Sharf T, Balkina A, et al. (2003). Interaction of the water-soluble protein aprotinin with liposomes: gel-filtration, turbidity studies, and 31P NMR studies. J Liposome Res 13:213–29
- Üstündağ-Okur N, İlem-Özdemir D, Görgülü Kahyaoğlu Ş, et al. (2015). Assessment of aprotinin loaded microemulsion formulations for parenteral drug delivery: preparation, characterization, in vitro release and cytotoxicity studies. Curr Drug Deliv 12:668–79
- Wilding IR, Coupe AJ, Davis SS. (1991). The role of gamma scintigraphy in oral drug delivery. Adv Drug Deliv Rev 7:87–117
- Ying W, Ke-Chun W, Bing-Xiang Z, et al. (2011). A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. J Biomed Biotechnol 2011:854872. doi: 10.1155/2011/854872